Literature DB >> 22406545

EMT as the ultimate survival mechanism of cancer cells.

Neha Tiwari1, Alexander Gheldof, Marianthi Tatari, Gerhard Christofori.   

Abstract

Epithelial cancers make up the vast majority of cancer types and, during the transition from benign adenoma to malignant carcinoma and metastasis, epithelial tumor cells acquire a de-differentiated, migratory and invasive behavior. This process of epithelial-mesenchymal transition (EMT) goes along with dramatic changes in cellular morphology, the loss and remodeling of cell-cell and cell-matrix adhesions, and the gain of migratory and invasive capabilities. EMT itself is a multistage process, involving a high degree of cellular plasticity and a large number of distinct genetic and epigenetic alterations, as fully differentiated epithelial cells convert into poorly differentiated, migratory and invasive mesenchymal cells. In the past years, a plethora of genes have been identified that are critical for EMT and metastasis formation. Notably, the EMT process not only induces increased cancer cell motility and invasiveness but also allows cancer cells to avoid apoptosis, anoikis, oncogene addiction, cellular, senescence and general immune defense. Notably, EMT seems to play a critical role in the generation and maintenance of cancer stem cells, highly consistent with the notion that metastatic cells carry the ability to initiate new tumors.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406545     DOI: 10.1016/j.semcancer.2012.02.013

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  194 in total

1.  Microenvironmental interactions and expression of molecular markers associated with epithelial-to-mesenchymal transition in colorectal carcinoma.

Authors:  Sun-Jae Lee; Chun-Seok Yang; Dae-Dong Kim; Yu-Na Kang; Sang Gyu Kwak; Jae-Bok Park; Chang-Ho Cho; Kwan-Kyu Park
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  The involvement of survivin in insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer.

Authors:  Chengjun Li; Jinbao Li; Dawei Wu; Gang Han
Journal:  Tumour Biol       Date:  2015-08-14

3.  Notch-1-mediated esophageal carcinoma EC-9706 cell invasion and metastasis by inducing epithelial-mesenchymal transition through Snail.

Authors:  Tao Wang; Xiaoyan Xuan; Linping Pian; Ping Gao; Hong Hu; Yuling Zheng; Wenqiao Zang; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2014-02

4.  Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets.

Authors:  David W Clark; Komaraiah Palle
Journal:  Ann Transl Med       Date:  2016-12

Review 5.  Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.

Authors:  Reem Malek; Hailun Wang; Kekoa Taparra; Phuoc T Tran
Journal:  Cells Tissues Organs       Date:  2017-02-20       Impact factor: 2.481

6.  miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.

Authors:  X Zhu; H Shen; X Yin; L Long; C Xie; Y Liu; L Hui; X Lin; Y Fang; Y Cao; Y Xu; M Li; W Xu; Y Li
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

Review 7.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

8.  Kir2.1 Interaction with Stk38 Promotes Invasion and Metastasis of Human Gastric Cancer by Enhancing MEKK2-MEK1/2-ERK1/2 Signaling.

Authors:  Cheng-Dong Ji; Yan-Xia Wang; Dong-Fang Xiang; Qiang Liu; Zhi-Hua Zhou; Feng Qian; Lang Yang; Yong Ren; Wei Cui; Sen-Lin Xu; Xi-Long Zhao; Xia Zhang; Yan Wang; Peng Zhang; Ji-Ming Wang; You-Hong Cui; Xiu-Wu Bian
Journal:  Cancer Res       Date:  2018-03-16       Impact factor: 12.701

9.  Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.

Authors:  Chun-Xiong Zhao; Chun-Li Luo; Xiao-Hou Wu
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

10.  EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Authors:  Heather M Moore; Maria E Gonzalez; Kathy A Toy; Ashley Cimino-Mathews; Pedram Argani; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2013-03-29       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.